anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for the management of acute postoperative pain as part of a multimodal strategy to reduce opioid use, relieve pain, and reduce chronic pain in non-cardiac surgery. However, significant concerns arise in cardiac surgery due to the potential adverse effects of NSAID including increased bleeding and acute kidney injury (AKI). We hypothesized that NSAIDs are effective against pain and safe in the early postoperative period following cardiac surgery, taking contraindications into account.
METHODS: The KETOPAIN trial is a prospective, double blind, 1:1 ratio, versus placebo multicentric trial, randomizing 238 patients scheduled for cardiac surgery. Written consent will be obtained for all participants. The inclusion criterion is patients more than 18 years old undergoing for elective cardiac surgery under cardiopulmonary bypass (CPB). Patients will be allocated to the intervention (ketoprofen) group (n = 119) or the control (placebo) group (n = 119). In the intervention group, in addition to the standard treatment, patients will receive NSAIDs (ketoprofen) at a dose of 100 mg each 12 h 48 h after. The control group, in addition to the standard treatment, will receive a placebo of NSAIDs every 12 h for 48 h after surgery. An intention-to-treat analysis will be performed. The primary endpoint will be the intensity of acute postoperative pain at rest at 24 h from the end of surgery. Pain will be assessed using the numerous rating scale. The secondary endpoints will be postoperative pain on coughing during chest physiotherapy, postoperative pain until day 7, the pain trajectory between day 3 and day 7, cumulative opioid consumption within 48 h after surgery, nausea and vomiting, the occurrence of postoperative pulmonary complications within the first 7 days after surgery, neuropathic pain at 3 months, and quality of life at 3 months.
DISCUSSION: NSAIDs function as non-selective, reversible inhibitors of the cyclooxygenase enzyme and play a role in a multimodal pain management approach. While there are recommendations supporting the use of NSAIDs in major non-cardiac surgery, recent guidelines do not favor their use in cardiac surgery. However, this is based on low-quality evidence. Major concerns regarding NSAID use in cardiac surgery patients are potential increase in postoperative bleeding or AKI. However, few studies support the possible use of NSAIDs without the risk of bleeding and/or AKI. Also, in a recent French survey, many anesthesiologists reported using NSAIDs in cardiac surgery. To date, no large randomized study has been conducted to evaluate the efficacy of NSAIDs in the management of postoperative pain in cardiac surgery. The expected outcome of this study is an improvement in the management of acute postoperative pain in cardiac surgery with a multimodal strategy including the use of NSAIDs.
TRIAL REGISTRATION: ClinicalTrials.gov NCT06381063. Registered on April 24, 2024.
Participants will undergo irreversible electroporation (IRE) using the NanoKnife system. About 1 week following IRE, study participants will receive a 200mg dose of pembrolizumab.
Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
In each full year of the grant, this program will serve a minimum of 250 community-based fathers or expectant fathers (custodial or noncustodial) who are age 18 and older and who have a child or children under the age of 24. While the program will be targeted to fathers, mothers may also be served, as might individuals who play a father figure role such as adoptive fathers, foster fathers, grandfathers, etc. Ignite will serve the geographic area of Sarasota, Manatee, and Charlotte counties on the Gulf Coast of Florida. The goals of the program are to help struggling fathers and father figures improve the parent-child relationship, sustain healthy marriages and relationships (and help those who are single identify ways to enter into safe and supportive relationships that may ultimately lead to marriage), and identify and support fathers in their economic stability and employment objectives. These outcomes will be achieved through the provision of a series of workshops addressing responsible parenting and marriage and relationships as well as a complement of employment services and comprehensive case management. Additional services needed by participants will be identified and provided either through the extensive wraparound programming provided by JFCS or through collaborative agreements with local partner agencies.

Additionally, Ignite will incorporate a comprehensive employment program combining both job and career advancement. This will help fathers in crisis reach improved financial stability, which will in turn improve the ability of individual participants to be better parents and better partners, furthering the goals to foster more stable parent-child relationships and promote healthy marriages in the region. Nationwide 35% of children live in single parent families. Growing up in a single-parent family increases a child's risk of growing up poor, becoming a teen parent, dropping out of school, and disconnecting from the labor market. Coupled with its successful history of providing healthy marriage programming, JFCS as an agency is well-positioned to help families in crisis (both due to current economic conditions and in more long-term tenuous situations) become more stable and self-sufficient. Notable within our local demographic data is a significantly higher than average rate of unemployment and higher percentages of income in the past 30 days less than $500. Understanding the inextricable link between financial security and family stability, Ignite is truly targeting and reaching the most vulnerable individuals based solely on economic risk factors.
AIMS: An assessor-blinded randomized controlled trial was conducted to assess the effect of a culturally tailored low-glycaemic index (GI) dietary educational intervention on body mass index and cardiometabolic risks for Chinese people with obesity in Hong Kong.
METHODS AND RESULTS: A total of 166 Chinese adults in Hong Kong with obesity were randomized to the intervention group (n = 83) or the control group (n = 83). The intervention group received the culturally sensitive low-GI dietary educational intervention based on the health belief model, consisting of an educational booklet, one individual interactive educational session, and three follow-up telephone calls. The control group received general advice on a healthy diet, including a pamphlet, one individual education session, and three follow-up telephone calls. Outcome measures included body mass index, cardiometabolic risk factors, dietary intake variables, and sense of satiety. Data collection was conducted at baseline and post-intervention at 12 weeks. A generalized estimating equation model was used to compare the difference in changes in outcome variables between groups. Compared with the control group, the intervention group exhibited a significant reduction in dietary glycaemic load (β = -6.963, P = 0.026) at post-intervention. No significant effects were found on other outcomes.
CONCLUSION: A 12-week culturally tailored and health belief model-based low-GI dietary educational intervention significantly reduced the dietary glycaemic load and showed the feasibility of the low-GI dietary intervention in Chinese adults in Hong Kong with obesity. A longer intervention period and follow-up might be required to achieve improvements in reducing cardiometabolic risk factors in people with obesity.
REGISTRATION: ClinicalTrials.gov: NCT04152213.
The present invention relates to a peptide and its application for preparation of medicine for treating inflammatory diseases, wherein the peptide comprises an amino acid sequence as shown in SEQ ID NO:1, and the medicine comprises an effective dose of the peptide and a pharmaceutically acceptable carrier. In addition, the peptide is used as an application of medicine for treating pain, and the medicine comprises an effective dose of the peptide and a pharmaceutically acceptable carrier. The present invention proves that the administration of the peptide can effectively reduce the inflammatory marker and relieve pain. The inflammatory diseases include ankylosing arthritis, osteoarthritis, rheumatic arthritis, rheumatoid arthritis, traumatic arthritis, pyogenic arthritis, gouty arthritis, tuberculous arthritis, neurogenic arthritis, and hemophilic arthritis. The pain includes neuropathic pain, inflammatory pain, musculoskeletal pain, pain after surgery, cancer pain, acute pain, and chronic pain. The inflammatory pain includes ankylosing arthritis pain, osteoarthritis pain, rheumatic arthritis pain, rheumatoid arthritis pain, traumatic arthritis pain, pyogenic arthritis pain, gouty arthritis pain, tuberculous arthritis Pain, neurogenic arthritis pain, and hemophilic arthritis pain. The medicine is in an enteral or parenteral dosage form. The enteral dosage form is an oral dosage form. The parenteral dosage form is an injection form. The effective dose is ranged from 0.0008 [mu]g/kg to 815 [mu]g/kg. The pharmaceutically acceptable carrier includes a solvent, an emulsifier, a suspending agent, a disintegrant, a binder, an excipient, a stabilizer, a diluent, a gelling agent, a preservative, a lubricant or a surface active agent. The present invention further provides a method for treating inflammatory diseases, comprising the steps of administering a therapeutically effective amount of a peptide to a desired receptor, wherein the peptide comprises the amino acid sequence as shown in SEQ ID NO:1 or its variant. The variant comprises an amino acid sequence having at least 80% identity with SEQ ID NO:1.
A man in his 50s was diagnosed with solar urticaria following monochromated light testing that demonstrated exquisite photosensivity to ultraviolet (UV) A, UV B (UVB) and visible light.Treatment options for this photodermatosis are limited; UVB phototherapy is one modality that can be appropriate in some patients. This is administered at very low doses in a controlled environment to induce skin hardening.1 To self-treat his condition, the patient used a commercial sunbed on two occasions several days apart. He noted an immediate flare of solar urticaria after first use with associated dizziness. Following the second use, he felt generally unwell and was witnessed to lose consciousness and displayed jerky movements of his limbs while a passenger in a car. Investigations including a head MRI and an EEG were normal; an anoxic seizure caused by a flare of solar urticaria was later confirmed.Solar urticaria is a rare photodermatosis that is poorly understood and difficult to treat. The condition has a significant impact on the quality of life of patients. Severe cases can be associated with systemic symptoms that could be life-threatening.
A kit and method for individual, family, or community psychological wellness diagnosis and a treatment for health enhancement are disclosed. The diagnosis is nursing compatible and based on Carl Jung's concepts of archetypes and synchronicity theory, and the treatment based on aromatherapy science and acupuncture theory. The kit includes a box with a plurality of containers and instructions for using the contents of the containers. Each container is labeled with one Jungian archetype and contains a unique aromatic substance. The method of the invention involves presenting the open box to the client or agent for assessment so that no more than a uniformity of top enclosures are visible, and timing their blind pick of one container. The picked archetype plus the timed number are both diagnostic; each supplies syntax for a psychological diagnosis of wellness health. A synchronicity time map supplies diagnosis words that bear like diagnostic meaning in three sciences: nursing, acupuncture, and Christian Science healing.
The invention relates to novel application of Dendrobium officinale, and aims to provide application of Dendrobium officinale in preparing medicaments for treating low gastric acidity type chronic atrophic gastritis. The invention discloses application of Dendrobium officinale in preparing medicaments for treating low gastric acidity type chronic atrophic gastritis and a Dendrobium officinale-based preparation method of medicaments for treating low gastric acidity type chronic atrophic gastritis. The invention provides a new means for treating low gastric acidity type chronic atrophic gastritis. The medicaments of the invention have the effects of relieving weight loss, gastric mucosa inflammation, gastric atrophy, dysplasia and intestinal metaplasia, and also have an effect of significantly increasing gastric acid secretion. The Tiepifengdou granules of the invention have a mild formulation, are suitable for conditioning and rehabilitation of spleen and stomach diseases with deficiency-excess complications caused by weakness of the spleen and the stomach or sthenia symptoms caused by asthenia. Traditional Chinese medicine has good safety in treatment and can be administered for a long term, and has the comprehensive effects of consolidating therapeutic effect, preventing recurrence, regulating the whole body and so on.
B cell targeted therapies have become a key element in the treatment of multiple sclerosis due to their effectiveness in rapid and long-lasting depletion of B cells in peripheral blood (PB), significantly reducing relapse rates and disability progression. The monoclonal antibodies OFA, OCR, UBX, and RTX target the B cell surface protein CD20, however it is unclear how B cell depletion and subsequent repopulation allows for immune system reconstitution and how other immune cell populations are affected by these therapies. Furthermore, the relevance of immune cell changes - beyond B cell depletion - for clinical disease stability remains insufficiently understood.

By collecting comprehensive and structured prospective clinical data alongside immunological analyses, this study aims for a better understanding of immunological changes in RRMS patients receiving anti-CD20 therapies and the implications of those alterations in immune cell profiles on the clinical disease course. REBELLION-MS plans for two patient cohorts: cohort 1 (C1; basic cohort) and cohort 2 (C2; in-depth cohort). Participants in C1 will be seen every 6 months up until month 24, then every 12 months. The following parameters will be collected: demographic data, disease characteristics incl. Expanded Disability Status Scale (EDSS) and magnetic resonance imaging (MRI) data, serum samples, and Peripheral Blood Mononuclear Cells (PBMCs). Furthermore, Short Form-36 (SF-36) and Fatigue Scale for Motor and Cognitive Functions (FSMC) are documented. Participants of C2 will receive additional evaluations: clinical evaluation incl. EDSS and sampling of serum and PBMCs at months 1 and 3, Multiple sclerosis functional composite (MFSC) every 6 months, and optical coherence tomography (OCT) as well as neuropsychological assessment (NPT) every 12 months. Serum samples and PBMCs will be analyzed by mFC, bulk-Seq, TCR/BCR-Seq, and proteomics, among other methods.
###  Teratogenic Effects

Animal reproduction studies have not been conducted with vancomycin. It is not known whether vancomycin can affect reproduction capacity. In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin on infants were evaluated when the drug was administered to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. One infant whose mother received vancomycin in the third trimester experienced conductive hearing loss that was not attributed to the administration of vancomycin. Because the number of patients treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not known whether vancomycin causes fetal harm. Vancomycin should be given to a pregnant woman only if clearly needed.
Nocturnal scratching substantially impairs the quality of life in individuals with skin conditions such as atopic dermatitis (AD). Current clinical measurements of scratch rely on patient-reported outcomes (PROs) on itch over the last 24 h. Such measurements lack objectivity and sensitivity. Digital health technologies (DHTs), such as wearable sensors, have been widely used to capture behaviors in clinical and real-world settings. In this work, we develop and validate a machine learning algorithm using wrist-wearing actigraphy that could objectively quantify nocturnal scratching events, therefore facilitating accurate assessment of disease progression, treatment effectiveness, and overall quality of life in AD patients. A total of seven subjects were enrolled in a study to generate data overnight in an inpatient setting. Several machine learning models were developed, and their performance was compared. Results demonstrated that the best-performing model achieved the F1 score of 0.45 on the test set, accompanied by a precision of 0.44 and a recall of 0.46. Upon satisfactory performance with an expanded subject pool, our automatic scratch detection algorithm holds the potential for objectively assessing sleep quality and disease state in AD patients. This advancement promises to inform and refine therapeutic strategies for individuals with AD.
BACKGROUND: Obesity has increased in recent years with consequences on diabetes and other comorbidities. Thus, 1 out of 3 diabetic patients suffers cardiovascular disease (CVD). The network among glucose, immune system, endothelium and epicardial fat has an important role on pro-inflammatory and thrombotic mechanisms of atherogenesis. Since semaglutide, long-acting glucagon like peptide 1- receptor agonist (GLP-1-RA), a glucose-lowering drug, reduces body weight, we aimed to study its effects on human epicardial fat (EAT), aortic endothelial cells and neutrophils as atherogenesis involved-cardiovascular cells.
METHODS: EAT and subcutaneous fat (SAT) were collected from patients undergoing cardiac surgery. Differential glucose consumption and protein cargo of fat-released exosomes, after semaglutide or/and insulin treatment were analyzed by enzymatic and TripleTOF, respectively. Human neutrophils phenotype and their adhesion to aortic endothelial cells (HAEC) or angiogenesis were analyzed by flow cytometry and functional fluorescence analysis. Immune cells and plasma protein markers were determined by flow cytometry and Luminex-multiplex on patients before and after 6 months treatment with semaglutide.
RESULTS: GLP-1 receptor was expressed on fat and neutrophils. Differential exosomes-protein cargo was identified on EAT explants after semaglutide treatment. This drug increased secretion of gelsolin, antithrombotic protein, by EAT, modulated CD11b on neutrophils, its migration and endothelial adhesion, induced by adiposity protein, FABP4, or a chemoattractant. Monocytes and neutrophils phenotype and plasma adiposity, stretch, mesothelial, fibrotic, and inflammatory markers on patients underwent semaglutide treatment for 6 months showed a 20% reduction with statistical significance on FABP4 levels and an 80% increase of neutrophils-CD88.
CONCLUSION: Semaglutide increases endocrine activity of epicardial fat with antithrombotic properties. Moreover, this drug modulates the pro-inflammatory and atherogenic profile induced by the adiposity marker, FABP4, which is also reduced in patients after semaglutide treatment.
AIM: The aim of this work was to investigate the incidence of enterocutaneous fistula (ECF), including both small bowel and colonic fistulas, in a defined population of 1.04 million during a 10-year period and to describe aetiology, treatments, care consumption and outcome.
METHOD: A comprehensive search algorithm including diagnostic and procedural codes, enterostomal therapy nurse notes and in-hospital care for >60 days yielded 1970 search hits. After reviewing medical records, 187 patients with ECF were identified.
RESULTS: The annual incidence of ECF was 2.3 per 100 000, the incidence of ECF with intestinal failure type II was 0.9 per 100 000. Spontaneous closure of the fistula occurred in 16.0% of patients, while closure was seen in 97.3% of patients who underwent reconstructive surgery with recurrences in 6.7% and 8.3%, respectively. Cumulative ECF-related in-hospital care until closure or end of follow-up was 4 (range 0-61) weeks. Eighty-eight patients (47%) received home-based healthcare including parenteral feeding and/or fistula wound care. The estimated overall mortality at 1, 3 and 5 years was 33.7%, 42.1% and 47.6% respectively. Mortality was mainly in patients without spontaneous closure or reconstructive surgery, and the risk of ECF-related death was 30.2%.
CONCLUSION: This study defines the population-based incidence of ECF and reports a high overall mortality rate. Initial survivors were characterized by either spontaneous closure or eligibility for later reconstructive surgery, but with an eventual mortality rate of approximately 20%. ECF patients are high consumers of care: 55.1% needed ≥4 weeks in hospital and many received home-based healthcare.
FIELD: medicine. ^ SUBSTANCE: present invention refers to production of new vaccines and methods of treating the diseases associated with canine influenza virus. The method of immunisation of a dog against influenza virus involves introduction to a specified dog of a therapeutically effective amount of the vaccine containing at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog, and the amount of the specified virus is 10 to 10000 GA units, and the vaccine additionally contains an adjuvant where the adjuvant can be chosen from the metabolised adjuvant, b) the non-metabolised adjuvant, c) 2% alum, d) 5% alum, e) Quil A, and f) cholesterol or any combination thereof. The method for preparing the vaccine against canine influenza virus includes making the composition containing the therapeutically effective amount of at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog. Application of the vaccine prepared by the method for immunisation of dogs against influenza virus. ^ EFFECT: invention provides higher immunisation effectiveness. ^ 12 cl, 7 tbl
This irrigating solution should be used according to standard format for each surgical procedure. Follow directions of the particular administration set to be used. Remove the outer overwrap. Clean and disinfect the rubber stopper by using a sterile alcohol wipe. Insert the spike aseptically into the bag through the target area of the rubber stopper. Allow the fluid to flow and remove air from the tubing before irrigation begins.
<P>PROBLEM TO BE SOLVED: To provide prescriptions of γ-hydroxybutyrate salt in an aqueous medium, that are resistant to microbial growth.  <P>SOLUTION: The γ-hydroxybutyrate salt and a pH adjusting substance are mixed in an aqueous medium. As the pH adjusting substance, an organic acid or an inorganic acids is used. As the examples of the former, malic acid, citric acid, acetic acid and lactic acid are listed. As the examples of the latter, hydrochloric acid, sulfuric acid, boric acid and a nitric acid are listed. The composition is used for treatment of alcohol or opium withdrawal, reduced levels of growth hormone, increased intracranial pressure and physical pain in a patient.  <P>COPYRIGHT: (C)2009,JPO&INPIT